About
Bottneuro AG is a Swiss startup based in Basel, founded in January 2021. The company operates in the medical devices and equipment sector, focusing on personalized neurostimulation therapies for neurological diseases, particularly Alzheimer's disease. Its main product, Miamind®, is a non-invasive neurostimulation device designed for home use. Miamind® utilizes MRI-based, 3D-printed caps to deliver targeted transcranial electrical stimulation at gamma frequencies. This device aims to improve cognition, reduce pathological tau protein levels, and slow the progression of Alzheimer's disease. It is registered as a Custom Made Device with Swissmedic, MHRA, and EUDAMED, allowing it to be prescribed for various conditions, including stroke and depression. Bottneuro has completed its first human study and is currently treating patients in Switzerland. The company plans to expand into Germany, the UK, and beyond, with efforts underway for FDA and CE approvals. With a team of 10 to 19 employees and an estimated revenue of 1 to 5 million CHF, Bottneuro is recognized in the TOP 100 Swiss Startup Ranking and has partnerships with institutions like ETH Zurich and industry players such as Samsung.
Technologies
Keywords
Company Information
-
Employees 11
-
Founded 2021
Location
35 Lichtstrasse, Basel, Basel-Stadt, Switzerland, 4056
